Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Akebia Ther

AKBA
Current price
1.36 USD +0.01 USD (+0.74%)
Last closed 1.39 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 305 683 136 USD
Yield for 12 month +106.06 %
1Y
3Y
5Y
10Y
15Y
AKBA
21.11.2021 - 28.11.2021

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. Address: 245 First Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5 USD

P/E ratio

Dividend Yield

Current Year

+194 623 000 USD

Last Year

+292 602 000 USD

Current Quarter

+56 196 000 USD

Last Quarter

+42 046 000 USD

Current Year

+118 889 000 USD

Last Year

+207 806 000 USD

Current Quarter

+37 136 000 USD

Last Quarter

+24 037 000 USD

Key Figures AKBA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -6 868 000 USD
Operating Margin TTM 5.26 %
PE Ratio
Return On Assets TTM -9.31 %
PEG Ratio
Return On Equity TTM -553.45 %
Wall Street Target Price 5 USD
Revenue TTM 194 623 008 USD
Book Value -0.16 USD
Revenue Per Share TTM 1.04 USD
Dividend Share
Quarterly Revenue Growth YOY 0.7 %
Dividend Yield
Gross Profit TTM 140 039 000 USD
Earnings Share -0.28 USD
Diluted Eps TTM -0.28 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin -26.68 %

Dividend Analytics AKBA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AKBA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AKBA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1.5973
Price Sales TTM 1.5706
Enterprise Value EBITDA -76.8173
Price Book MRQ 4.1167

Financials AKBA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AKBA

For 52 weeks

0.59 USD 2.48 USD
50 Day MA 1.62 USD
Shares Short Prior Month 10 126 415
200 Day MA 1.3 USD
Short Ratio 1.73
Shares Short 13 400 139
Short Percent 6.47 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics